leadf
logo-loader
viewAvacta Group PLC

Avacta Group's Bach BioSciences deal 'an exciting step'

Capital Network analyst Riccardo Lowi discusses Avacta Group Plc's (LON:AVCT) development partnership with Bach BioSciences as well as the news it's making shares available via subscription and a placing to bring in £11.4mln.

Lowi says the R&D collaboration with Bach is a very exiting step, potentially leading to a pre-clinical deal with big pharma in the next 12-18 month.

On Avacta's fundraise, he says the move should support operations well into calendar year 2020.

Quick facts: Avacta Group PLC

Price: 181 GBX

AIM:AVCT
Market: AIM
Market Cap: £457.3 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

BioIndustry Association marks 'golden age of biotech'

Dr Martin Turner who's head of policy and public affairs at the BioIndustry Association tells Proactive London it's a golden age of biotech currently with many more people wanting to get involved and invest in the sector. He says for newcomers to the space it's important they familiarise...

on 4/9/20

2 min read